|
Breast Cancer
is the most common form of cancer in North
American women and the second leading cause
of death surpassed only by lung cancer. One
in every eight women in North America will
develop breast cancer in her lifetime; for
some women the risk is even greater.
The STAR
Trial
A
Study of Tamoxifen and Raloxifene
BULLETIN: STAR HAS NOW COMPLETED THE ENROLLMENT PHASE OF THE STUDY AND IS NOW IN THE FOLLOW-UP PHASE OF THE TRIAL, WITH OVER 19,000 PARTICIPANTS ENROLLED
SEE THE ATTACHED REPORT FROM NCI, "Initial Results of the Study of Tamoxifen and Raloxifene (STAR) Released: Osteoporosis Drug Raloxifene Shown to be as Effective as Tamoxifen in Preventing Invasive Breast Cancer" DATED APRIL 17, 2006. CLICK download report TO SEE THE REPORT.
FOR MORE INFORMATION:
Contact Prevention Director, Bernadette Bensman, RN at (937) 395-8678 or by E-Mail
at bernadette.bensman@wright.edu.
To find out
more about this trial you can go to the NSABP
web site or the NCI
web site.
|
